Table 1

Characteristics of the subjects

Subject no	Sex	Age (years)	FEV₁ (% pred)	PC₂₀(mg/ml)	Eosinophils (%)	NO (ppb)
Steroid treated group
1	M	24	77	0.07	1.4	5.85
2	M	24	104	0.37	3.8	10.75
3	M	21	104	0.39	5.8	11.81
4	F	23	88	0.55	7.6	5.28
5	F	20	83	0.71	4.0	3.42
6	M	24	103	0.72	0.0	8.24
7	M	23	94	1.29	3.6	10.21
8	F	24	101	1.81	0.2	7.25
9	F	21	99	2.05	NA	2.17
10	M	28	104	2.54	3.4	2.15
11	F	21	98	3.14	1.4	3.92
12	M	27	99	3.14	0.2	4.62
		23.3 (2.4)^1-151	96.2 (9.0)^1-151	0.91 (1.62)^1-150	2.85 (2.46)^1-151	6.30 (3.34)^1-151
Placebo group
13	M	24	82	0.11	21.2	13.41
14	F	21	108	0.11	0.0	6.57
15	M	29	111	0.14	24.6	12.05
16	M	34	83	0.30	0.0	4.17
17	M	21	98	0.46	1.6	13.40
18	M	24	80	0.54	NA	14.08
19	M	25	86	0.73	0.0	3.26
20	M	24	98	0.77	1.8	4.22
21	F	24	106	0.89	3.2	2.48
22	M	28	90	1.00	1.2	3.36
23	F	28	106	1.20	NA	5.05
24	F	25	98	1.51	0.0	5.82
25	M	19	97	1.70	0.4	9.26
		25.1 (3.9)^1-151	95.6 (10.6)^1-151	0.52 (1.38)^1-150	4.91 (8.98)^1-151	7.47 (4.37)^1-151

FEV₁ = forced expiratory volume in one second; PC₂₀ = provocative concentration of histamine causing a 20% fall in FEV₁; NO = exhaled nitric oxide; NA = not applicable.
↵1-150 Geometric mean (SD) in doubling doses.
↵1-151 Mean (SD).